Authors: Hoffman, MA Ohh, M Yang, HF Klco, JM Ivan, M Kaelin, WG

Citation: Ma. Hoffman et al., von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF, HUM MOL GEN, 10(10), 2001, pp. 1019-1027

Authors: Ivan, M Kondo, K Yang, HF Kim, W Valiando, J Ohh, M Salic, A Asara, JM Lane, WS Kaelin, WG

Citation: M. Ivan et al., HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O-2 sensing, SCIENCE, 292(5516), 2001, pp. 464-468

Authors: Ohh, M Park, CW Ivan, N Hoffman, MA Kim, TY Huang, LE Pavletich, N Chau, V Kaelin, WG

Citation: M. Ohh et al., Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein, NAT CELL BI, 2(7), 2000, pp. 423-427

Authors: O'Hagan, RC Ohh, M David, G de Alboran, IM Alt, FW Kaelin, WG DePinho, RA

Citation: Rc. O'Hagan et al., Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression, GENE DEV, 14(17), 2000, pp. 2185-2191

Authors: Ohh, M Kaelin, WG

Citation: M. Ohh et Wg. Kaelin, The von Hippel-Lindau tumour suppressor protein: new perspectives, MOL MED TOD, 5(6), 1999, pp. 257-263

Authors: Ohh, M Takagi, Y Aso, T Stebbins, CE Pavletich, NP Zbar, B Conaway, RC Conaway, JW Kaelin, WG

Citation: M. Ohh et al., Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein, J CLIN INV, 104(11), 1999, pp. 1583-1591